<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144802</url>
  </required_header>
  <id_info>
    <org_study_id>FOX</org_study_id>
    <nct_id>NCT05144802</nct_id>
  </id_info>
  <brief_title>Accuracy of Dexcom G6® and FreeStyle Libre® Sensors in Standardized Hypoxemia Conditions</brief_title>
  <official_title>Accuracy of Dexcom G6® and FreeStyle Libre® Sensors in Standardized Hypoxemia Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major aim is to evaluate accuracy of 2 Continuous Glucose Monitoring Systems (CGMS) :&#xD;
      Dexcom G6® and FreeStyle Libre® in standardized hypoxemia conditions (artificial normobaric&#xD;
      hypoxia).&#xD;
&#xD;
      Our purpose is to demonstrate the good performance and calibration of these CGM sensors in&#xD;
      hypoxemia conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess accuracy of interstitial glucose values measured respectively by FreeStyle® Libre and Dexcom® G6 compared to blood glucose values in standardized hypoxemia conditions in patients with diabetes and in healthy volunteers.</measure>
    <time_frame>Day 1</time_frame>
    <description>Mean absolute relative difference (MARD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of acute hypoxia</measure>
    <time_frame>Day 1</time_frame>
    <description>Arterial blood oxygen saturation (Sp02)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of acute hypoxia</measure>
    <time_frame>Day 1</time_frame>
    <description>Lake Louise Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>group 1 : FreeStyle Libre 2 on right arm and Dexcom G6 on left arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : FreeStyle Libre 2 will be applied on right arm and Dexcom G6 will be applied on left arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 : 2 FreeStyle Libre 2 on left arm and Dexcom G6 on right arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : Dexcom G6 will be applied on right arm and FreeStyle Libre 2 will be applied on left arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>acute hypoxia</intervention_name>
    <description>Participants will be exposed to a 3-hour acute hypoxia</description>
    <arm_group_label>group 1 : FreeStyle Libre 2 on right arm and Dexcom G6 on left arm</arm_group_label>
    <arm_group_label>group 2 : 2 FreeStyle Libre 2 on left arm and Dexcom G6 on right arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: all population&#xD;
&#xD;
          -  No history of respiratory diseases (childhood asthma, respiratory allergies,&#xD;
             exercise-induced asthma or dyspnea)&#xD;
&#xD;
          -  Willing to participate and able to sign an informed consent form (ICF)&#xD;
&#xD;
          -  Being affiliated with the French Social Security&#xD;
&#xD;
        Inclusion Criteria:Patients with diabetes&#xD;
&#xD;
          -  type 1 diabetes mellitus or type 2 diabetes mellitus (ADA definition)&#xD;
&#xD;
          -  Age : 18 to 75 years&#xD;
&#xD;
          -  stable diabetes treatment for more than 3 months&#xD;
&#xD;
          -  no diabetic retinopathy&#xD;
&#xD;
          -  no diabetic neuropathy&#xD;
&#xD;
          -  no cardiovascular diseases&#xD;
&#xD;
          -  no contra-indication for coronary computed tomography angiography or myocardial&#xD;
             perfusion scintigraphy.&#xD;
&#xD;
        Inclusion Criteria: Healthy volunteers&#xD;
&#xD;
          -  Age : 18 ; 40 years&#xD;
&#xD;
          -  No diabetes&#xD;
&#xD;
          -  No persistant drug use &gt; 3 months except contraception&#xD;
&#xD;
          -  Body mass index : [18,5 - 29,9] kg/m2&#xD;
&#xD;
        Non-inclusion criteria : all population&#xD;
&#xD;
          -  Active smokers&#xD;
&#xD;
          -  Pregnant or breastfeeding women, women of childbearing age without effective&#xD;
             contraception&#xD;
&#xD;
          -  Known allergies to the patch.&#xD;
&#xD;
          -  Skin lesions at the sensor site that may interfere with sensor placement or accuracy&#xD;
&#xD;
          -  Major cardiovascular complications within the past 3 months&#xD;
&#xD;
          -  Decompensated congestive heart failure&#xD;
&#xD;
          -  Chronic respiratory failure&#xD;
&#xD;
          -  Chronic renal failure&#xD;
&#xD;
          -  Resting ambient air O2 saturation ≤95%.&#xD;
&#xD;
          -  Treatment with systemic corticosteroids&#xD;
&#xD;
          -  Severe hypertension (≥180 mmHg systolic pressure or ≥ 100 mmHg diastolic pressure)&#xD;
&#xD;
          -  Any concomitant disease or condition that the investigator believes may compromise&#xD;
             patient safety or affect the conduct of the study&#xD;
&#xD;
          -  Anemia (Hb&lt;12g/dl)&#xD;
&#xD;
          -  History of severe mountain sickness&#xD;
&#xD;
          -  Concurrent participation in another clinical research study,&#xD;
&#xD;
          -  Persons benefiting from enhanced protection&#xD;
&#xD;
        Non-inclusion criteria: Patients with diabetes&#xD;
&#xD;
          -  Absolute contraindications to physical activity (HAS definitin) :&#xD;
&#xD;
          -  Pulmonary arterial hypertension (&gt; 60 mm Hg)&#xD;
&#xD;
          -  Presence of intra-cardiac thrombus&#xD;
&#xD;
          -  Acute pericardial effusion&#xD;
&#xD;
          -  Severe obstructive cardiomyopathy&#xD;
&#xD;
          -  Symptomatic aortic stenosis&#xD;
&#xD;
          -  Recent thrombophlebitis with or without pulmonary embolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BONNIN Marie</last_name>
    <phone>+33(0)5 49 44 33 17</phone>
    <email>marie.bonnin@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>SAULNIER Pierre-Jean, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CGM (Continuous Glucose Monitoring)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

